Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Association of Computed Tomography Phenotypic Signature With Progression-free Survival in Stage IV EGFR-mutant Non-small Cell Lung Cancer Undergoing Tyrosine Kinase Inhibitors

NCT02851329 is registered in ClinicalTrials.gov with Chinese Academy of Sciences as lead sponsor.

NCT NCT02851329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02851329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Association of Computed Tomography Phenotypic Signature With Progression-free Survival in Stage IV EGFR-mutant Non-small Cell Lung Cancer Undergoing Tyrosine Kinase Inhibitors
Lead sponsor
Chinese Academy of Sciences
Phase
Observational
Overall status
Unknown status
Start date
February 28, 2015
Completion date
July 31, 2017
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer